MEI Pharma Inc (MEIP) News

Form 8-K - Current report

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its...

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

MEI Pharma Reports Fiscal Year End 2024 Cash Position

Confirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its...

MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives

MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that it has engaged Oppenheimer & Co. Inc. to serve as the Company’s...

Form 8-K - Current report